These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9590666)

  • 1. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
    Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
    J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of citalopram in body dysmorphic disorder.
    Phillips KA; Najjar F
    J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
    Phillips KA; Albertini RS; Rasmussen SA
    Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness.
    Hollander E; Allen A; Kwon J; Aronowitz B; Schmeidler J; Wong C; Simeon D
    Arch Gen Psychiatry; 1999 Nov; 56(11):1033-9. PubMed ID: 10565503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases.
    Phillips KA; McElroy SL; Keck PE; Hudson JI; Pope HG
    Psychopharmacol Bull; 1994; 30(2):179-86. PubMed ID: 7831453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness.
    Phillips KA; Menard W; Pagano ME; Fay C; Stout RL
    J Psychiatr Res; 2006 Mar; 40(2):95-104. PubMed ID: 16229856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder.
    Phillips KA; Siniscalchi JM; McElroy SL
    Psychiatr Q; 2004; 75(4):309-20. PubMed ID: 15563049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective pilot study of levetiracetam for body dysmorphic disorder.
    Phillips KA; Menard W
    CNS Spectr; 2009 May; 14(5):252-60. PubMed ID: 19407724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight in obsessive compulsive disorder and body dysmorphic disorder.
    Eisen JL; Phillips KA; Coles ME; Rasmussen SA
    Compr Psychiatry; 2004; 45(1):10-5. PubMed ID: 14671731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine alone in the treatment of delusional depression.
    Gatti F; Bellini L; Gasperini M; Perez J; Zanardi R; Smeraldi E
    Am J Psychiatry; 1996 Mar; 153(3):414-6. PubMed ID: 8610832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic treatment of body dysmorphic disorder.
    Phillips KA
    Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label study of escitalopram in body dysmorphic disorder.
    Phillips KA
    Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.
    Saxena S; Winograd A; Dunkin JJ; Maidment K; Rosen R; Vapnik T; Tarlow G; Bystritsky A
    J Clin Psychiatry; 2001 Jan; 62(1):67-72; quiz 73. PubMed ID: 11235937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5.
    Phillips KA; Hart AS; Simpson HB; Stein DJ
    CNS Spectr; 2014 Feb; 19(1):10-20. PubMed ID: 23659348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body image disturbance in body dysmorphic disorder and eating disorders. Obsessions or delusions?
    Phillips KA; Kim JM; Hudson JI
    Psychiatr Clin North Am; 1995 Jun; 18(2):317-34. PubMed ID: 7659601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.